Tran Laboratory
Phuoc Tran, M.D., Ph.D.
Principal Investigator
Areas of Research
- Animal Models
- Artificial Intelligence
- Bioinformatics
- Bladder Cancer
- Cancer Biology
- Cancer Genomics
- Cancer Metastasis
- DNA Damage Response
- Gastrointestinal Cancer
- Genomics
- Liver Cancer
- Lung Cancer
- Molecular and Cellular Oncology
- Mouse Model Development
- Next Generation Sequencing
- Pancreatic Cancer
- Prostate Cancer
- Radiation Oncology
- Radiation Therapy
- Radiopharmaceuticals
- Targeted Therapy
- Tumor Microenvironment
Welcome to the Tran Laboratory at MD Anderson! The Tran Lab's overarching goal is to translate our basic findings in genitourinary, lung and gastrointestinal cancers into novel approaches to improve the prevention, diagnosis and treatment of human malignancies.
Scroll Ahead
- Departments, Labs and Institutes
- Labs
- Tran Laboratory
About the Tran Lab
Dr. Tran and his laboratory have been continuously funded by both the federal government (National Institutes of Health [NIH] and Department of Defense [DoD]) and foundations for over a decade. Research in the Tran Lab focuses on:
- Pathways critical for the development, progression and maintenance of genitourinary (prostate and bladder), lung and gastrointestinal (liver and pancreas) cancers
- Tumor cell epithelial plasticity programs such as the epithelial-mesenchymal transition (EMT) and their implications for tumorigenesis, metastasis, metabolism, treatment resistance, and radiation-induced fibrosis
- Novel targeted agents as tumor selective radiosensitizers to increase the therapeutic ratio of clinical radiotherapy
- The use of inducible mouse models to simulate molecularly targeted therapies for malignancies and radiation-induced late effects
Our research utilizes a variety of transgenic mouse models and non-invasive imaging as well as traditional molecular, biochemical and cell biology approaches.
TWIST1 and HOXA9 are coexpressed in the developing mouse prostate and in autochthonous prostate neoplastic lesions.
Twist1 overexpression in vivo is sufficient to cause erlotinib resistance.
Griseofulvin reduced centrosome clustering in NSCLC cells after radiation treatment.
Twist1 structure and domains critical for metastasis functions.
The hexosamine biosynthetic pathway (HBP) and glycosylated EMT targets.
Centrosome clustering inhibition induces micronuclei and activates cGAS.
The oligometastatic disease state.